Carlyle Group to buy 20% stake in Piramal Enterprises’ arm
27th Jun 2020

CA Clover Intermediate II Investments, an affiliated entity of CAP V Mauritius, an investment fund managed and advised by affiliated entities of The Carlyle Group Inc. has agreed to invest fresh equity capital for a 20% stake in Piramal Enterprises’ wholly owned subsidiary -- Piramal Pharma. The estimated equity capital investment in Piramal Pharma would amount to over Rs 3,700 crore. The final amount of equity investment will depend on the net debt, exchange rate and performance against the pre-agreed conditions at the time of closing of the deal.

Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.